Dongkook Pharmaceutical to Pursue Name Change to DK Centellian

Dongkook Pharmaceutical is planning to change its name to "DK Centellian" in a bid to strengthen its global presence and venture into the health and beauty market. The company announced on October 12 that its board had approved the proposal, reflecting its ambition to leverage its nearly six decades of pharmaceutical experience while exploring new growth opportunities worldwide.

Traditionally concentrating on the domestic pharmaceutical market, Dongkook Pharmaceutical intends to diversify its operations to include prevention, treatment, health, and beauty services, with the goal of becoming a science-based health and beauty enterprise with a stronger international focus. The name "DK Centellian" merges the company's 58-year history, scientific credibility, and corporate foundation with its aspirations for future growth.

The change seeks to reflect a broader business vision and forge a stronger connection with customers globally. By expanding beyond its current pharmaceutical operations, Dongkook Pharmaceutical aims to create a more diversified business portfolio that combines its existing strengths with opportunities in the health and beauty sectors.

This strategic shift is expected to bolster the company's efforts to establish a more prominent brand presence in international markets. The rebranding process requires approval through an extraordinary general meeting of shareholders on November 27, during which amendments to the company's articles of incorporation will be considered.

The proposed name change encapsulates Dongkook Pharmaceutical's commitment to maintaining its rich heritage while creating new value through its accumulated expertise, signaling the company's determination to evolve from a domestically centered pharmaceutical business into a globally oriented health and beauty enterprise with heightened brand recognition.